Paeds · allergy-and-immunology
Anaphylaxis prevention, action plans and autoinjectors
Also known as ASCIA anaphylaxis action plan · Adrenaline autoinjector · EpiPen · Anapen · Anaphylaxis first-aid · School anaphylaxis management · Biphasic anaphylaxis
Fellowship topic on the complete community prevention and first-aid package for a child at risk of anaphylaxis: trigger identification and avoidance, the written personalised ASCIA action plan (green for the mild-to-moderate allergic reaction, red for anaphylaxis), prescribing and teaching the weight-appropriate adrenaline autoinjector (0.15 mg device for 7.5-20 kg, 0.3 mg for 20 kg and over, 0.5 mg for 50 kg and over where available), correct intramuscular technique into the outer mid-thigh, family and school education, the biphasic reaction and the mandatory observation pathway, the fatal-risk triad of adolescence with peanut or tree-nut allergy and uncontrolled asthma, and adolescent transition planning. The page names ASCIA, EAACI, WAO and the US 2020 practice parameter guideline positions and the regional deltas, and defends the adrenaline-first principle.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A child with a known food allergy who develops hoarseness, throat tightness, drooling, persistent cough, wheeze or collapse — this is anaphylaxis on the red plan; give adrenaline now, do not treat it as asthma or anxiety
- The adolescent with peanut or tree-nut allergy and uncontrolled asthma who does not carry the autoinjector — the classic fatal-anaphylaxis triad; rebuild the prevention plan around device-carrying and asthma control
- A reaction that looked mild but involved more than one body system, or any airway, breathing or cardiovascular sign — escalate from the green plan to adrenaline; the single decision the plan exists to make
- A child who has been given adrenaline in the community — every single use mandates ambulance transfer and hospital observation for the biphasic window, even if the child has fully recovered
- The child who stands, sits up, or walks during anaphylaxis — sudden fatal empty-vena-cava cardiovascular collapse; lie the child flat and do not let them mobilise
- An expired or absent autoinjector at the moment of reaction — system failure is the preventable cause of paediatric anaphylaxis death
Life stages
Care settings
Clinical exam formats
Board mappings
- Allergy and Immunology: written anaphylaxis action plans and adrenaline autoinjector prescribing, weight-appropriate dosing and carer education
- General Paediatrics: prevention of recurrent anaphylaxis — trigger avoidance, school liaison and the biphasic observation pathway
- Allergy and Immunology (Renewed curriculum): longitudinal prevention package, weight-band transitions, adolescent transition and management of complex multi-allergy and high-risk asthma-plus-food-allergy children
- Community and population child health: school anaphylaxis readiness, rural and remote access to adrenaline and equity of autoinjector access
- General Paediatrics: a child with a first anaphylactic reaction — the prevention prescription, the action plan and family/school education
- Pharmacology and Therapeutics: adrenaline pharmacology, the intramuscular route rationale and autoinjector device technique
- Long Case and Structured discussion: the adolescent with peanut anaphylaxis and uncontrolled asthma — risk stratification, prevention package and transition planning
- Communication station: counselling a family and a school on the action plan, device technique and when to use adrenaline
- Level 2 and 3 — Allergy: anaphylaxis prevention, written action plans and adrenaline autoinjector prescribing and technique
- Public health and safeguarding: school readiness for anaphylaxis and the safety-net for the high-risk adolescent
- Applied Knowledge in Practice (AKP): adrenaline autoinjector weight bands, the biphasic reaction and management of anaphylaxis in the community
- Foundation of Practice (FOP): recognition of anaphylaxis and the written action plan framework
- Communication: explaining an ASCIA anaphylaxis action plan and demonstrating autoinjector technique to a parent and a teacher
- History-taking and management: the child with a first anaphylactic reaction — the prevention prescription and follow-up plan
- General Pediatrics Content Outline — Allergy and Immunology: prevention of anaphylaxis, epinephrine autoinjector selection and patient and caregiver education
- Emergency Care: community first-aid management of anaphylaxis, biphasic reactions and disposition
- Patient Care: prescribe and teach an age- and weight-appropriate adrenaline autoinjector and a written anaphylaxis action plan
- Systems-Based Practice: school and community readiness, spare-autoinjector access and rural access to adrenaline
- Medical Knowledge: adrenaline pharmacology, the intramuscular route, biphasic reactions and the fatal-risk profile of adolescence
- Medical Expert: anaphylaxis prevention, written action plans and adrenaline autoinjector prescribing and technique
- Health Advocate and Collaborator: school anaphylaxis policy, adolescent transition and equitable access to adrenaline
- Communicator: counselling the family, child and school on the action plan and device technique
The numbers that shape the prevention package
Overview & Definition
Imagine a six-year-old with a peanut allergy sitting in a school lunch area. In the next ten minutes one of two things will happen: either nothing, because everyone knew the trigger, carried the plan and the device, and the food was kept away — or a collapse, and in that collapse the difference between life and death is whether a written plan and an adrenaline autoinjector exist on site and whether someone present can use them. This page is about building that package so reliably that the second scenario is survivable. [10]
Anaphylaxis prevention in children is the structured, longitudinal package that converts a potentially fatal allergic emergency into a treatable community event. It rests on five pillars: identification and avoidance of the trigger, a written personalised action plan, a prescribed adrenaline autoinjector, education of the child and every carer, and a medical alert plus a second device. The package is global, but its drugs, weight bands and named documents are regional — in Australia and Aotearoa New Zealand it is delivered through the ASCIA plans and devices, in Europe through the EAACI framework, and in North America through the AAAAI/ACAAI 2020 practice parameter. [5] [4]
In Australasia, the written documents are the ASCIA Action Plan for Anaphylaxis (red) and the ASCIA Action Plan for Allergic Reactions (green). Adrenaline autoinjector devices available include EpiPen and Anapen. The weight bands are 7.5 to 20 kg for the 0.15 mg device and 20 kg and over for the 0.3 mg device, with a 0.5 mg Anapen available for 50 kg and over.
The concept to hold is that prevention here is layered. Primary prevention is stopping food allergy from developing in the first place — the LEAP trial proved that early rather than delayed peanut introduction in high-risk infants cuts peanut allergy, and that upstream work reduces the downstream population this page's package exists to protect. [14] Secondary prevention is what happens after the diagnosis: avoidance, preparedness, the plan and the device. Tertiary prevention is preventing the next reaction from killing once anaphylaxis has already occurred — adrenaline without delay, the second dose, ambulance, observation. Every paragraph below sits inside one of these three layers. [9]
References14ShowHide
- [1]Sampson HA; Muñoz-Furlong A; Campbell RL; Adkinson NF Jr; Bock SA; Branum A; Brown SG; Camargo CA Jr; Cydulka R; Galli SJ; Gidudu J; Gruchalla RS; Harlor AD Jr; Jopner DL; Kaplan AP; Levy JH; Lisenby WF; Méndez-Inocencio J; Nowak-Węgrzyn A; Oppenheimer JJ; Sclar DA; Sheffer AL; Sferdeen L; Yocum MW Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol, 2006.PMID 16461139
- [2]Brown SG Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol, 2004.PMID 15316518
- [3]Simons FE; Ardusso LR; Bilò MB; El-Gamal YM; Ledford DK; Ring J; Sanchez-Borges M; Senna GE; Sheikh A; Thong BY; Worm M; World Allergy Organization 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol, 2012.PMID 22744267
- [4]Shaker MS; Wallace DV; Golden DBK; Oppenheimer J; Bernstein JA; Campbell RL; Dinakar C; Ellis A; Greenhawt M; Khan DA; Lang DM; Lierl MB; Padial A; Rank MA; Stukus DR; Wang J; Cassidy-Smith M; Cush J; Hershey MS; Hogue SL; Kachru R; Kanaley J; Portnoy JM; Schilling LH; Stahl AL; Tadigotla V; Vargas PA; Wasserman R; Zampelli A Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol, 2020.PMID 32001253
- [5]Muraro A; Worm M; Alviani C; Cardona V; DunnGalvin A; Gowland MH; language review team; Angood E; Arroyave-Sánchez L M; Beck S; Belohlávek J; Bindslev-Jensen C; Bøgh KL; Brockow K; Fernández-Rivas M; Garvey LH; Gómez C; Halken S; Jensen BM; Khaleva E; Knol EF; Kolkhir P; Kurowski M; Lopata AL; Lozoya I; Michaelis LJ; Mohapatra A; Oude Elberink H N G; Panesar SS; Pavão R; Regent A; Ribeiro C; Santos A F; Silva R; Sokolova E; Søndergaard KB; Stensgaard A; Söderström L; Tedner M; Tøttenborg SS; Trautmann A; Turner PJ; Uyttebroek A; Vazquez-Ortiz M; Vlieg-Boerstra B; Weritz N; Yazdanbakhsh M; Zawadzka-Krajewska A; EAACI Guidelines Committee EAACI guidelines: Anaphylaxis (2021 update). Allergy, 2022.PMID 34343358
- [6]Muraro A; Roberts G; Worm M; Bilò MB; Brockow K; Fernández Rivas M; Santos AF; Zolkipli ZQ; Bellou A; Beyer K; Bindslev-Jensen C; Cardona V; DunnGalvin A; Foucard T; de Groot H; Garvey LH; Hourihane J; Kowalski M; Kuitunen M; Lebens AF; McBride D; Oude Elberink H; Papi A; Rancé F; Riemer A; Ring J; Sampson H; Slapke I; Sturm G; Vlieg-Boerstra B; Wöhrl S; Wickman M; Sheikh A; EAACI Food Allergy and Anaphylaxis Guidelines Group Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy, 2014.PMID 24909803
- [7]Liew WK; Williamson E; Tang ML Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol, 2009.PMID 19117599
- [8]Mullins RJ; Wainstein BK; Barnes EH; Liew WK; Campbell DE Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy, 2016.PMID 27144664
- [9]Simons FE First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol, 2004.PMID 15131564
- [10]Sicherer SH; Simons FER; SECTION ON ALLERGY AND IMMUNOLOGY Epinephrine for First-aid Management of Anaphylaxis. Pediatrics, 2017.PMID 28193791
- [11]Turner PJ; Jerschow E; Umasunthar T; Lin R; Campbell DE; Boyle RJ Fatal Anaphylaxis: Mortality Rate and Risk Factors. J Allergy Clin Immunol Pract, 2017.PMID 28888247
- [12]Lee S; Bellolio MF; Hess EP; Erwin P; Silber MC; Campbell RL Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis. J Allergy Clin Immunol Pract, 2015.PMID 25680923
- [13]Mehr S; Liew WK; Tey D; Tang ML Clinical predictors for biphasic reactions in children presenting with anaphylaxis. Clin Exp Allergy, 2009.PMID 19486033
- [14]Du Toit G; Roberts G; Sayre PH; Bahnson HT; Radulovic S; Santos AF; Brough HA; Phippard D; Basting M; Feeney M; Turcanu V; Sever ML; Gomez Lorenzo M; Plaut M; Lack G; LEAP Study Team Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med, 2015.PMID 25705822